AIM ImmunoTech to Present at the Q1 Virtual Investor Summit on March 24th

by Barry101 | Mar 11, 2021 | Press Release, Uncategorized

OCALA, Fla., March 11, 2021 — via InvestorWire – AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, will be presenting at the Q1 Virtual Investor Summit.  Event  Q1...

AIM ImmunoTech to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference

by Barry101 | Mar 10, 2021 | Press Release, Uncategorized

OCALA, Fla., March 10, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, AIM’s Chief Executive Officer, has been invited to present at the Inaugural Emerging Growth Virtual Conference, presented by M Vest LLC and Maxim...

AIM ImmunoTech Announces First Healthy Subjects Dosed in Phase 1 Intranasal Ampligen Clinical Study

by Barry101 | Mar 8, 2021 | Press Release, Uncategorized

Marks important milestone towards development of Ampligen as a potential prophylaxis or treatment for COVID-19 and other respiratory viral diseasesOCALA, Fla., March 08, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has dosed the first...

AIM ImmunoTech to Present at the H.C. Wainwright Global Life Sciences Conference on March 9th

by Barry101 | Mar 4, 2021 | Press Release, Uncategorized

OCALA, Fla., March 04, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, will be presenting at the H.C. Wainwright Life Sciences Conference to be held virtually between March 9-10,...

AIM ImmunoTech’s Subsidiary Receives Orphan Medicinal Product Designation by the European Medicines Agency for Ampligen to Treat Pancreatic Cancer

by Barry101 | Feb 24, 2021 | Press Release, Uncategorized

OCALA, Fla., Feb. 24, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) today announced that its subsidiary, NV Hemispherx Biopharma Europe, has received formal notification from the European Commission (EC) approving the company’s Orphan Medicinal Product...

AIM ImmunoTech Announces Ethics Committee Approval to Commence Phase 1 Clinical Study of Ampligen as an Intranasal Therapy

by Barry101 | Feb 16, 2021 | Press Release, Uncategorized

OCALA, Fla., Feb. 16, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has received approval from the required Ethics Committee in the Netherlands to commence its Phase 1 clinical study on the safety of AIM’s drug Ampligen as an...